|Bid||109.63 x 300|
|Ask||109.65 x 100|
|Day's Range||109.35 - 110.35|
|52 Week Range||79.12 - 112.97|
|PE Ratio (TTM)||22.07|
|Dividend & Yield||1.80 (1.64%)|
|1y Target Est||N/A|
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.
There’s something uniquely American about the heat of summer; it’s also a great time to pour some money into some US-based stocks